Version May 2024
Note: Manufacturer dosing recommendations based on 70 kg patient.
Diagnostic imaging: Oral:
Thyroid imaging: 0.4 mCi (14.8 MBq); alternatively, a range of 0.2 to 0.4 mCi (7.4 to 14.8 MBq) has been recommended (Ref).
Uptake studies: 0.1 mCi (3.7 MBq). Note: If uptake studies are performed in conjunction with thyroid imaging, the dose administered for imaging will suffice (Ref).
Thyroid cancer metastases (evaluation/localization) (off-label) (Ref): Oral: 0.4 to 5 mCi (14.8 to 185 MBq).
Thyroid imaging as an adjunct in parathyroid scintigraphy (off-label) (Ref): Oral: 0.2 to 0.6 mCi (7.5 to 22 MBq).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
Thyroid imaging (off-label; (Ref)): Children and Adolescents: Oral: 0.006 mCi/kg (0.2 MBq/kg)
Dosing range: Minimum administered activity: 0.025 mCi (0.925 MBq); Maximum administered activity: 0.4 mCi (14.8 MBq)
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Cardiovascular: Chest pain, tachycardia
Dermatologic: Pruritus, skin rash, urticaria
Gastrointestinal: Nausea, vomiting
There are no contraindications listed in the manufacturer’s labeling.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Concurrent drug therapy issues:
• Iodine/thyroid medications: Concomitant use of iodine, thyroid, or antithyroid medications may interfere with the uptake of radioiodide; medications should be discontinued for an appropriate time prior to dosing.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, Oral:
Generic: 3.7 MBq [0.1 mCi], 7.4 MBq [0.2 mCi]
No
Capsules (Sodium Iodide I-123 Oral)
3.7 mbq (per each): $130.02
7.4 mbq (per each): $199.97
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For oral administration. Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn at all times when handling.
Oral: Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn at all times when handling.
Diagnostic agent: Evaluation of thyroid function and/or morphology
Thyroid cancer metastases (evaluation/localization); Thyroid imaging as an adjunct to parathyroid scintigraphy; Visualization of retrosternal thyroid tissue
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
The manufacturer recommends elective studies be conducted during the first few (~10) days following menses in women of reproductive potential.
Animal studies have not been conducted. All radiopharmaceuticals have the potential to cause fetal harm.
The amount of sodium iodide I123 excreted in breast milk is variable, relating to a number of factors including thyroid uptake and renal clearance of the radioiodide.
If the sodium iodide I123 product is free from radionuclide contaminants, interruption of breast-feeding may not be necessary. However, if the sodium iodide I123 product contains radionuclide contaminants, breast-feeding should be interrupted for a time ranging from 24 hours to complete cessation depending on the level of contamination (Stabin, 2000).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
